Moderna’s Vaccine Supply agreement amended

After Pfizer Inc and its German partner BioNTech SE agreed to push back deliveries of their Covid-19 vaccines to the European Union now Moderna, Inc.(NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, last week announced an agreement with the European Commission (EC) to amend their originally agreed contractual delivery schedules for the Moderna COVID-19 vaccine booster product (Spikevax, mRNA-1273) or updated boostervaccine candidate.
On the basis of this agreement, the company will postpone the delivery of some doses initially planned for quarter 2 of 2022, to later in the year.
June 2, Stella Kyriakides, Commissioner for Health and Food Safety, said: “This is the second agreement with vaccine manufacturers to optimise supply arrangements and align them with current demand levels in our Member States. I very much welcome today’s agreement on more flexible delivery arrangements for the Moderna vaccine to respond to our Member States’ needs. We continue to closely monitor the situation and stand ready to provide further support to Member States national vaccination campaigns.”